View Older Stories View More Recent Stories

Nov 16, 2020 04:21PM Bristol Myers Squibb Provides Regulatory Update on Lisocabtagene Maraleucel (liso-cel)
Nov 11, 2020 04:15PM Bristol Myers Squibb to Participate in Wolfe Research’s 2nd Annual Virtual Healthcare Conference
Nov 11, 2020 06:59AM Bristol Myers Squibb Showcases Research Advancing Outcomes Addressing Hard-to-Treat Blood Cancers and Diseases Across Small Molecule, Biologic and Cell Therapies at ASH 2020
Nov 9, 2020 07:27PM Bristol Myers Squibb Prices $7 Billion of Senior Unsecured Notes
Nov 9, 2020 06:59AM Bristol Myers Squibb Presents Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis
Nov 6, 2020 06:59AM Bristol-Myers Squibb (BMY) Receives EC Approval for Opdivo plus Yervoy with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic NSCLC
Nov 6, 2020 06:59AM Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Ca
Nov 5, 2020 07:01AM Bristol Myers Squibb Data at ACR Convergence 2020 Underscore Commitment to Advancing Science for Patients with Difficult-to-Treat Immune-Mediated Diseases
Nov 5, 2020 06:59AM Bristol Myers Squibb Reports Third Quarter 2020 Financial Results
Nov 4, 2020 07:00AM Bristol-Myers Squibb (BMY), MyoKardia (MYOK) Announce Expiration of HSR Act Waiting Period
Nov 4, 2020 06:59AM Bristol Myers Squibb and MyoKardia Announce Expiration of HSR Act Waiting Period
Nov 3, 2020 07:00AM Bristol-Myers Squibb (BMY) Announces Deucravacitinib Demonstrated Superiority to Placebo and Otezla in Pivotal Phase 3 Psoriasis Study
Nov 3, 2020 06:59AM Bristol Myers Squibb Announces Deucravacitinib (BMS-986165) Demonstrated Superiority to Placebo and Otezla® (apremilast) in Pivotal Phase 3 Psoriasis Study
Oct 26, 2020 08:00AM Decreases in Americans' Primary Care Visits May Lead to Late Diagnoses of Potentially Serious Conditions¹
Oct 19, 2020 07:00AM Bristol-Myers Squibb (BMY) Announces FDA Accepts for Priority Review Applications for OPDIVO in Combination with CABOMETYX in Advanced Renal Cell Carcinoma
Oct 19, 2020 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma
Oct 16, 2020 07:46AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Opdivo as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic ESCC
Oct 16, 2020 07:45AM Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Oct 12, 2020 05:47AM Bristol-Myers Squibb (BMY) Reports Positive Late-Breaking Data from Ph. 3 True North Trial Evaluating Zeposia (ozanimod)
Oct 10, 2020 06:06PM Bristol Myers Squibb Presents Positive Late-Breaking Data from Phase 3 True North Trial Evaluating Zeposia (ozanimod) in Adult Patients with Moderate to Severe Ulcerative Colitis
Oct 8, 2020 01:50AM Evotec Achieves Milestone in Its Neurodegeneration Collaboration with Bristol Myers Squibb
Oct 7, 2020 07:03AM Bristol-Myers Squibb (BMY) Reports Opdivo (nivolumab) Plus Chemotherapy Shows Statistically Significant Improvement in Phase 3 CheckMate -816 Trial
Oct 7, 2020 06:59AM Opdivo (nivolumab) Plus Chemotherapy Shows Statistically Significant Improvement in Pathologic Complete Response as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate
Oct 5, 2020 06:30AM Bristol-Myers Squibb (BMY) to Acquire MyoKardia (MYOK) for $13.1 Billion in Cash, $225 Per Share
Oct 5, 2020 06:30AM Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
Oct 2, 2020 04:17PM Bristol Myers Squibb (BMY) Announces Update on CheckMate -915 Evaluating Opdivo Plus Yervoy Versus Opdivo in Resected High-Risk Melanoma Patients
Oct 2, 2020 04:17PM Bristol Myers Squibb Announces Update on CheckMate -915 Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo in Resected High-Risk Melanoma Patients
Oct 2, 2020 04:13PM Bristol-Myers Squibb (BMY) Confirms FDA Approves Opdivo + Yervoy as First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
Oct 2, 2020 04:12PM U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelio
Oct 2, 2020 06:59AM UNCF, Bristol Myers Squibb Announce Second Cohort of the Ernest E. Just Postgraduate Fellowship and Extension of Partnership Through 2026
Oct 2, 2020 06:59AM  Bristol Myers Squibb to Host Virtual Investor Event to Discuss Results from Phase 3 True North Trial Evaluating Zeposia® (ozanimod) in Ulcerative Colitis at UEG Week 2020
Sep 29, 2020 06:59AM Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living with Beta Thalassemia
Sep 24, 2020 04:21PM Bristol Myers Squibb (BMY) Said Opdivo Met Primary Endpoints in Pivotal Phase 3 Trial
Sep 24, 2020 04:15PM Opdivo (nivolumab) Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial
Sep 22, 2020 07:00AM Bristol Myers Squibb (BMY), bluebird (BLUE) Announce FDA Accepts for Priority Review Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleuce
Sep 22, 2020 06:59AM U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)
Sep 21, 2020 04:16PM Bristol Myers Squibb Completes Acquisition of Forbius
Sep 21, 2020 12:31PM Bristol-Myers Squibb (BMY) Announces Opdivo Plus Chemo Demonstrated Significant Overall and PFS Benefits Versus Chemotherapy in First-Line Treatment of Gastric and Esophageal Cancers
Sep 21, 2020 12:31PM Opdivo (nivolumab) Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to Placebo in the Adjuvant Setting
Sep 21, 2020 12:30PM Opdivo (nivolumab) Plus Chemotherapy Demonstrated Significant Overall and Progression-Free Survival Benefits Versus Chemotherapy in First-Line Treatment of Gastric and Esophageal Cancers
Sep 19, 2020 12:30PM Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial
Sep 18, 2020 07:18AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Approval of Opdivo Plus Yervoy Combined with Two Cycles of Chemotherapy as First-Line Treatment of Metastatic NSCLC
Sep 18, 2020 07:17AM Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Two Cycles of Chemotherapy as First-Line Treatment of Metastatic
Sep 17, 2020 04:16PM Bristol Myers Squibb to Announce Results for Third Quarter 2020 on November 5, 2020
Sep 17, 2020 07:00AM Bristol-Myers Squibb (BMY) Announces Settlement of U.S. Patent Litigation for REVLIMID With Dr. Reddy’s (RDY)
Sep 17, 2020 06:59AM Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID® (lenalidomide) With Dr. Reddy’s
Sep 17, 2020 06:20AM Bristol-Myers Squibb (BMY) 4-Year Data Continue to Show Superior, Long-Term Survival Benefit with Opdivo Plus Yervoy in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Sep 17, 2020 06:15AM Four-Year Data Continue to Show Superior, Long-Term Survival Benefit with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Sep 15, 2020 07:08AM Bristol-Myers Squibb (BMY) Announces EMA Validates its Type II Variation Application for Opdivo Plus Yervoy for First-line Treatment of Malignant Pleural Mesothelioma
Sep 15, 2020 06:59AM European Medicines Agency Validates Bristol Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for First-line Treatment of Malignant Pleural Mesothelioma
View More Recent Stories View Older Stories